Abstract: Phlorotannins (marine algal polyphenols) have been reported to exhibit benefi cial biological activities, serving as both antioxidants and anti-infl ammatory agents. Among marine algae, Ecklonia cava, a member of the Laminariaceae, is a very popular food regarded as healthy in Korea and Japan. Recently, benefi ts aff orded by phlorotannins in the treatment of various clinical conditions have been reported, but any therapeutic effects of such materials in the treatment of neurodegenerative diseases such as stroke remain unclear. Also, the mechanisms of action of the algal components remain poorly understood. In the present in vivo study, administration of Ecklonia cava polyphenols (ECP) at 10 mg/kg and 50 mg/kg intraperitoneally (i.p.) signifi cantly decreased infarct size and the extent of brain edema in the rat aft er induction of transient focal ischemia via middle cerebral artery occlusion (MCAO). Further, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay revealed dose-dependent blockage of neuronal apoptosis upon intravenous ECP treatment. Neurobehavioral tests performed over the 6 days after MCAO revealed a reduction in neurological motor performance in control animals, but administration of ECP (50 mg/kg i.p.) prevented this decline. In vitro, a significant neuroprotective effect of ECP was evident when cell viability was assayed aft er induction of H 2 O 2 -mediated oxidative stress, upon retinoic acid treatment, in the diff erentiated neuroblastoma cell line SH-SY5Y. Interestingly, ECP blocked the rise in cytosolic calcium, in a dose-dependent manner, in diff erentiated SH-SY5Y cells exposed to H 2 O 2 . Together, the results suggest that ECP exerts neuroprotective eff ects in the focally ischemic brain by reducing Ca 2+ -mediated neurotoxicity.
Introduction
Several studies on the cytotoxic action of Ca 2+ ions have appeared over the last 30 years [1] [2] [3] . In the nervous system, Ca 2+ ] i ), thus preventing apoptotic neuronal death. Th e benefi cial eff ects of polyphenols (which have powerful antioxidant actions) have been thoroughly explored. Such compounds are favorite candidates for prevention of catastrophic neuronal events. Recent reports have greatly added to the store of relevant information. Polyphenols are natural com pounds with a range of phenolic structures that are present at high levels in vegetables, fruits, grains, roots, fl owers, seeds, and teas [6] . Polyphenols are known to possess potent antioxidant properties; most studies on the health benefits afforded by these compounds have focused on the treatment of vascular diseases and cancers [7] [8] [9] . Polyphenols have been implicated in the prevention of neurodegenerative diseases, including stroke. The compounds protect neurons against oxidative damage and attenuate ischemic injury by interfering with the activity of inducible nitric oxide synthase, thus inhibiting lipid peroxidation and decreasing the extent of glial activation during reperfusion after a prior ischemic insult. This reduces the extent of the neuroinflammatory response [10] . Epidemiological studies have shown that high-level consumption of polyphenolic compounds can lower the risk of stroke [11, 12] . In addition, an increasing number of reports have evaluated the antioxidant properties of polyphenols from diverse natural products, focusing on possible neuroprotective actions. In this context, only very limited information is available on the polyphenols of marine plants. Among the natural sources of polyphenolic com pounds, brown algae is very popular as a health food in Korea and Japan. Ecklonia cava, a representative perennial brown alga of the Ecklonia group, is a member of the Laminariaceae family of the order Laminariales [13] . Marine algal polyphenols, termed phlorotannins, known from only brown algae, have been reported to exhibit several biological activities, including an antioxidative capacity [14, 15] , an antidiabetic action [16] , and an anti-amnesia ability [17] . However, the protective effects of phlorotannins from Ecklonia cava in terms of the development of cerebral ischemia have only rarely been investigated. Our earlier study revealed that a polyphenol-containing Ecklonia cava extract exerted a neuroprotective effect in animal models of global ischemia (data not shown; manuscript submitted).
In the present study, we investigated the effi cacy of Ecklonia cava polyphenols (ECP) in terms of protection against middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia in rats. We measured infarct volume and the extent of brain edema. To evaluate the protective eff ects of ECP in terms of neuronal apoptosis of the damaged cerebral cortex and striatum, and the neurological defi cits caused by MCAO, we used the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and neurological scoring to evaluate brain damage, employing the scaling system of Garcia et al. [18] . In vitro, we assayed the viability of a diff erentiated human neuroblastoma cell line, SH-SY5Y, after exposure to H 2 O 2 -induced oxidative stress, with or without ECP preconditioning. Finally, we performed Fura-2AM-loaded [Ca 2+ ] i measurements to evaluate ECP-induced inhibition of [Ca 2+ ] i -induced neurotoxicity. 
Materials and Methods

Materials
Experimental animals
Male Sprague-Dawley (SD) rats (Rattus norvegicus) were obtained from the Experimental Animal Center, Konyang University, Daejeon, South Korea. Rats were used at 4 months of age, at a body weight of 300-350 g. The animals were housed in a conventional manner at 23 o C and 60% relative humidity with a 12-hour light/12-hour dark cycle, and had free access to water and food. Animal handling and care conformed to our institutional guidelines; these, in turn, comply with international law and policy (see the NIH Guide for the Care and Use of Laboratory Animals; NIH Publication No. 85-23, 1985, revised 1996) . All experiments were designed to minimize the number of animals used and the suffering caused by our procedures.
Drug administration and surgery
A total of 64 adult male SD rats were used. Th e rats were divided into four groups, each of 16 individuals; the groups were termed sham-operated, operated, 10 mg/kg ECP-Anat Cell Biol 2012;45:103-113 105 www.acbjournal.org injected, and 50 mg/kg ECP-injected. All injections were intraperitoneal. In the latter two experimental groups, half of the final dose of ECP (diluted in phosphate buffer) was given 30 minutes before, and the other half 30 minutes aft er surgery. The following surgical method was used. The right middle cerebral artery (MCA) was occluded for 90 minutes using a modification of the intraluminal-suture insertion method [19, 20] , in which a nylon filament is introduced into the MCA. Employing this approach, the right common carotid artery was exposed and the occipital branches of the external carotid artery (ECA) were electrocauterized. A 4-0 monofilament nylon suture was next inserted, via the ECA, into the internal carotid artery and the MCA, located 20-22 mm from the carotid bifurcation. Prior to each procedure, the suture was coated with a poly-L-lysine solution to augment adhesion to the surrounding endothelium and to increase the reproducibility of the resulting infarct. Th e neck incision was next closed and each animal was allowed to waken from anesthesia. At 60 minutes aft er MCAO, each operated animal was tested, using a standardized neurobehavioral scale, to confirm the presence of a typical neurological deficit. Rats that did not show initial contralateral paralysis were excluded from further study. At 90 minutes aft er MCAO, rats were reanesthetized, the intraluminal suture was carefully removed, and each incision was closed. Rats in the sham-operated group were subjected to the same surgical procedure but the nylon suture was advanced for only about 10 mm and next immediately withdrawn. Aft er surgery, all operated rats were observed carefully for signs of discomfort and each of the four groups was further divided into four subgroups (of four animals each). These subgroups were subjected to different experimental tests, as described below. For example, one randomly selected subgroup (n=4) from each initial group (n=16) was subjected to varying types of neurobehavioral tests over the next 6 days. The remaining subgroups (n=12 animals in total) were sacrificed at different times after ischemic reperfusion (four rats at each timepoint) after the conduct of the various experiments described below.
Triphenyltetrazolium chloride (TTC) staining
To determine infarct volume, rats of individual subgroups (n=4 in each subgroup) were decapitated 24 hours after initiation of the post-ischemic reperfusion that followed MCAO. Each brain was removed and sliced into coronal sections 2.0 mm in thickness. Five brain slices from each rat were incubated in 2% (w/v) TTC solution for 10 minutes at 37 o C and next transferred to 4% (v/v) paraformaldehyde solution for fi xation. Normal brain tissue was uniformly red in color whereas infarcted regions were whitish. The first, third, and fifth post-fixation brain slices from each rat were photographed and the extent of the whitish areas calculated using the Adobe PhotoShop CS imaging system. To minimize artifacts in the infarct area produced by post-ischemic edema, and to correct for individual differences in brain volumes, the infarct volume was calculated as a percentage of the total brain area of each section. Th e images were not manipulated apart from adjustment of the background color to black.
Estimation of the extent of brain edema
To determine brain water content, rats in individual subgroups (n=4 for each subgroup) were decapitated 72 hours after commencement of the post-ischemic reperfusion that followed MCAO. Whole brains were obtained and the right hemispheres quickly isolated. Each sample was weighed on an electronic balance and dried in an oven at 100 o C for 24 hours [21] . Next, all samples were precisely weighed again and the water content (a percentage value) determined using the following formula: [(wet weight minus dry weight)/wet weight]×100%.
Tissue processing and TUNEL staining to detect apoptosis
Rats in individual subgroups (n=4 in each subgroup) were anesthetized with sodium pentobarbital and transcardially perfused with 0.1 M phosphate-buffered saline, pH 7.4, followed by 4% (v/v) paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Brains were removed and post-fixed in the same material for 6 hours. Brain tissue was dehydrated by successive immersion (for 2 hours each time) in 50%, 70%, 80%, 90%, 95%, and 100% (all v/v) ethanol baths at room temperature. Next, the slices were successively immersed, each time for 1 hour, in fresh pure xylene and in molds containing melted paraffin (Sigma, St. Louis, MO, USA). For each brain, 5 μm-thick serial transverse sections of the region containing both the cerebral cortex and striatum were mounted on microscope slides. To detect neuronal apoptosis, TUNEL staining was performed according to the protocol of the DeadEnd TM TUNEL detection system (Santa Cruz Biochemistry, Santa Cruz, CA, USA). Briefl y, for each rat, 10 randomly selected coronal paraffi nized sections were deparaffinized in xylene, hydrated by immersion in baths featuring a (decreasing) ethanol gradient, and washed in distilled water. Next, each section was incubated with a nucleotide-labeling mixture and terminal deoxynucleotidyl transferase, for 1 hour at 37 o C, to catalytically add the peroxidase-labeled digoxigenin nucleotide to DNA fragments. Nuclei displaying DNA cleavage were dark brown in appearance after addition of the chromogen 3,3'-diaminobenzidine tetrachloride (Sigma). We counted all TUNELpositive cells in a single microscopic field of each of 10 randomly selected sections of each target area (the cerebral cortex and the striatum of the right hemisphere).
Neurological scoring
Neurological evaluation of rats of individual subgroups (n=4 in each subgroup) was performed by two observers blinded to treatment, using the neurological scoring system of Garcia et al. [18] . Briefl y, on postoperative day 0 (PD 0; 2 hours aft er MCAO), PD 2, PD 4, and PD 6, animal behavior was evaluated employing six independent criteria. Th ese were spontaneous activity, symmetry of movements, outstretching of the forelimbs, wall climbing, reaction to body touch, and response to touching of the vibrissae. Th e results of the fi rst three tests were graded from 0 (severe defi cit) to 3 (no defi cit), but those of the latter three had a lowest score of 1. The grades were summed by each observer and the average scores obtained during two consecutive test sessions were calculated. Th e total score for each rat was 3 points at a minimum, and maximally 18.
Cell culture and diff erentiation
SH-SY5Y human neuroblastoma cells were purchased from ATCC (Manassas, VA, USA). Cells were plated in Dulbecco's modification of Eagle's medium Nutrient Mixture : Ham's F-12 (1 : 1, v/v) medium supplemented with 10% (v/ v) fetal bovine serum, penicillin (100 IU/ml), streptomycin (100 μg/ml), and L-glutamine (2 mM). Th e cells were grown on culture dishes precoated with poly-D-lysine (50 mg/ml in sterile water) overnight. Differentiation was induced by addition of 10 μM all-trans-retinoic acid (RA; Sigma) on day 2 after plating, and continued for 7 days. Every 48 hours, the medium was replaced with fresh medium containing 1% RA, supplemented with 1% (v/v) fetal bovine serum, 2 mM glutamine, and penicillin/streptomycin. Cultures were maintained at 37 o C in 95% air/5% CO 2 (both v/v) in a humidifi ed incubator. At 7 days aft er RA treatment, all cells exhibited extended neurite outgrowth. The RA-treated SH-SY5Y cells were used in the experiments described below. 
Resistance of cells to H 2 O 2 challenge
[Ca
2+
] i measurement SH-SY5Y cells were plated on coverslips for 2 days and further differentiated for 7 days by addition of 10 μM RA treatment. Each cell was incubated with ECP of varying amounts (0, 0.01, and 1 μg/ml) for 24 hours and then were loaded with 3 mM Fura-2AM (dissolved in DMSO), added to serum-free growth medium, at 37 o C for 1 hour in a CO 2 incubator, and were next washed with HEPES-buffered physiological saline containing 2.5 mM glucose, 137 mM NaCl, 0.56 mM MgCl 2 , 4.7 mM KCl, 1 mM Na 2 HPO 4 , 10 mM HEPES (pH 7.4), and 1.28 mM CaCl 2 . Th e coverslips bearing Fura-2AM-labeled cells were mounted in a perfusion chamber (Warner Instruments, Hamden, CT, USA) containing HEPESbuffered physiological saline and examined by inverted fluorescent microscopy (Till Photonics, Munich, Germany). Samples were scanned every 1 second using excitation at 340 nm and measuring emission at 380 nm. ] i were measured. All images were processed for analysis of any changes at the single-cell level. Th e results were expressed as relative fl uorescence intensity values [22] .
Statistical analysis
All data are presented as means±SEMs. Comparisons of the outcomes of different treatments were performed using Student's t-test (Sigma Plot ver. 8.02 software, SPSS Inc., Chicago, IL, USA). Diff erences with P<0.05 were considered to be statistically significant. Below, each "n" value refers to 
Results
Protective eff ects of ECP in terms of infarct area and extent of brain edema in a rat model of cerebral ischemia
In the present study, the neuroprotective effects of ECP in terms of focal ischemia were evaluated by measurement of infarcted areas and the extent of brain swelling. Twentyfour hours after reperfusion, infarcted areas were measured by TTC staining. Quantitative assessment of the total infarcted proportion of the brain areas of the fi rst, third, and fifth sections showed that intraperitoneal injection of 50 mg/kg ECP significantly reduced infarction. However, the infarct area of the 10 mg/kg ECP group was not signifi cantly reduced compared with that of the operated group (Fig.  1A, B) . The mean infarct areas in three representative slices from the operated group and the 50 mg/kg ECP group were 37.35±3.75% and 19.52±5.25% of total brain area, respectively. Th e extent of brain edema was also signifi cantly reduced by administration of 50 mg/kg ECP (Fig. 1C) . Although the reduction in the extent of brain edema seen when ECP was given at 10 mg/kg was not statistically signifi cant, a tendency toward dose-dependent reduction in the extent of such edema was evident aft er ECP treatment.
Eff ects of ECP on neuronal apoptosis
TUNEL-positive apoptotic neuronal cells were rarely present in either the cerebral cortex or the striatum of the sham-operated group (Fig. 2A) . In contrast, the numbers of apoptotic neuronal cells in either area were significantly larger in the operated group. As expected, a signifi cant dosedependent attenuation in the extent of neuronal apoptosis in both regions was evident in the ECP-treated groups. When ECP was given at 50 mg/kg, the numbers of TUNEL-positive cells in 10 randomly selected sections from each area were signifi cantly lower than those in the cerebral cortex (26.2±8.2 Quantitation of the summed proportions of infarct area (in terms of total brain area) in the fi rst, third, and fi ft h sections revealed that intraperitoneal injection of 50 mg/kg ECP significantly reduced the infarct area, compared to that of the operated group, whereas this was not the case when ECP was given at 10 mg/kg. The mean infarct areas in three representative slices from the operated group and the group treated with 50 mg/kg ECP were 37.35±3.75% and 19.52±5.25% of the total brain areas, respectively (n=4 per group, *P<0.05, signifi cantly diff erent from the operated group). (C) In ECP-treated groups, the brain water content was reduced, in a dose-dependent manner, compared to that of the operated group (n=4 per group, *P<0.05). (Fig. 2B) .
Eff ect of ECP on development of neurological defi cits
To determine the effect of ECP treatment on the development of ischemia-induced neurobehavioral deficits, postoperative motor defi cits evident in animals treated with the two different doses of ECP (10 mg/kg and 50 mg/kg) were compared with those of the operated group (lacking ECP treatment) using the neurological scoring system of Garcia. Rats of the sham-operated group showed slight neurobehavioral defi cits at PD 0, but all scores subsequently became normal. When the neurological scores of the group treated with 50 mg/kg ECP were compared with those of the operated group, a statistically significant enhancement of neurological performance was evident at all timepoints (12.5± 1.6 vs. 9±1.8 at PD 2, 14.4±0.8 vs. 10.2±1.6 at PD 4, 14.8±1.8 vs. 11.4±1.6 at PD 6; n=4 for each comparison; P<0.05 vs. operated) except for PD 0 (Fig. 3) . 
Effects of ECP on neuronal viability in the context of H 2 O 2 -induced oxidative stress
To further understand the neuroprotective mechanisms of ECP, we explored whether ECP treatment protected differentiated SH-SY5Y neuronal cells from H 2 O 2 -induced oxidative stress. As shown in representative cell features, we regarded SH-SY5Y cells at DIV7 as RA-induced fully differentiated states and used it in further studies (Fig. 4A) . Before conducting a cell viability assay using diff erent doses of ECP in the context of H 2 O 2 -induced damage, we determined the maximal safe dose of ECP under such conditions (Fig.  4B) . Additionally, we identified the timepoint at which cell viability was reduced to 50% of that of the control after exposure to 10 mM H 2 O 2 ; this was 7 hours. (Fig. 4C) . All experimental cells were transferred to normal growth medium at this time, allowed to recover for 17 hours, and the levels of MTT reduction recorded. Cells treated with ECP at concentrations of 0.1, 0.5, 1, or 10 μg/ml (dissolved in culture medium) for 24 hours prior to exposure to 10 mM H 2 O 2 had viabilities of 60.18±5.24%, 65.35±7.36%, 68.72±3.14%, and 65.32±6.60% of that of control cells, respectively (P<0.05, P<0.01 vs. control) (Fig. 4D) . Such a dose-dependent cytoprotective eff ect of ECP on diff erentiated neuroblastoma cells aft er challenge with H 2 O 2 -induced oxidative stress is in agreement with the results of the in vivo experiments. ] i and at least in part, may eventually increase neuronal survival.
ECP-mediated inhibition of the rise in
Discussion
Increasing evidence supports the hypothesis that polyphenols protect neurons against changes associated with cerebral ischemia [23] . Ischemic stroke is caused by an interruption of cerebral blood fl ow, which can lead to failure of energy production, activation of proteases, impairment of metabolism, free radical production, excitotoxicity, and altered calcium homeostasis [24] [25] [26] [27] . Cerebral ischemia is associated with a severe deterioration in the ability of neuronal mitochondria to function effectively; this seriously compromises oxidative phosphorylation, a key mechanism by which ATP is produced. Apart from ATP depletion, dysfunctional mitochondria may increase ROS production and are unable to maintain a normal [Ca 2+ ] i .
This causes depolarization of the cytoplasmic membrane potential. Such changes can contribute to both Ca 2+ -induced membrane damage and increase levels of Ca 2+ -induced proteases, the extent of ROS-mediated cell damage (to membranes and DNA) and lipid peroxidation [28] . Thus, potential neuroprotectants seek to reduce oxidative stress and mitochondrial damage. It is thus reasonable to suggest that the therapeutic use of polyphenols (which possess strong antioxidant activities) may reduce cell damage, thus improving cell viability, following cerebral ischemia [29] [30] [31] . Recently, knowledge of the beneficial roles played by polyphenols derived from terrestrial plants in protection from neurodegenerative diseases such as stroke has greatly increased, but only very limited information is available on the polyphenol components of marine plants. Brown algae are popular health foods in Korea and Japan. Ecklonia cava, a representative perennial brown alga of the Ecklonia group, is a member of the Laminariaceae of the order Laminariales [13] . As mentioned above, purified polyphenols from Ecklonia cava have been reported to exert multiple biological activities, although their neuroprotective effect of ECP on stroke has received only limited attention. In our previous study, ECP protected hippocampal slices of the gerbil from global ischemia induced by bilateral common carotid artery occlusion, consistent with in vitro data showing that ECP protected against oxygen-glucose deprivation-induced cytotoxic death of the SH-SY5Y cell line. Although these results were the first experimental demonstration of the neuroprotective efficacy of ECP in the context of cerebral ischemia, some fundamental limitations of the work are evident.
First, global ischemia is not the only form of cerebral To determine the maximal safe dose, diff erentiated SH-SY5Y cells were exposed to various concentrations of ECP (0.01-100 μg/ml) and cell viability was determined using the MTT assay (n=7 per group; *P<0.05, ***P<0.001). Th e results diff ered signifi cantly from those from control cells (lacking any ECP treatment). (C) Th e time aft er exposure to 10 mM H 2 O 2 at which cell viability was reduced to 50% of the control level was determined; this (7 h) was the optimal timepoint (indicated by the dotted line) for conduct of further cell viability studies (n=7 per group). (D) Cell viability assays were performed, using data from the experiments of Fig. 4B and C, and it was observed that cells treated with ECP at doses of 0.1, 0. ischemia. It is generally accepted that two types of ischemia exist: these are global ischemia, aff ecting wide areas of brain tissue, and focal ischemia, confined to a specific region of the brain. The former condition occurs when blood flow to the brain is halted, or drastically reduced, as when cardiac arrest occurs. The latter condition eventuates when a blood clot occludes a cerebral vessel; indeed, the condition is clinically less common than focal ischemia. To overcome this limitation, in the present study we adapted the focal ischemia model to permit in vivo screening of the therapeutic effi cacy of ECP in the context of cerebral ischemia. Second, although the human neuroblastoma cell line, SH-SY5Y, is commonly employed for in vitro neurotoxicological testing, because the cells were originally derived from neurons, are very sensitive to neuronal inhibitors, and are morphologically similar to neurons, doubts have been expressed concerning functional mimicry of neurons by such cells. To overcome this limitation, in the present study we used RA-induced differentiated SH-SY5Y cells to conduct supportive in vitro experiments. Indeed, SH-SY5Y cells can differentiate, both morphologically and functionally, into neuron-like cells when cultured in the presence of low levels of RA [32] [33] [34] . Such differentiation, accompanied by neurite extension, is also associated with increased electrical excitability of the cytoplasmic membrane [35] and alterations in the expression levels of certain G-protein coupled receptor subunits [36] . Given that a neuron-like phenotype is shown by differentiated SH-SY5Y cells, the present study was undertaken to examine changes in cell viability and [Ca 2+ ] i aft er pretreatment with diff erent amounts of ECP. We also considered the effects of ECP on post-ischemic brain edema. Such edema is an essential component of ischemic injury [37] , being characterized by abnormal accumulation of exudate in the parenchyma, resulting in volumetric enlargement of the tissue. Acute brain edema usually radically affects clinical prognosis after occurrence of ischemia, because edema can lead to brain herniation, irreversible brain damage, and, eventually, death. Brain edema is of two distinct types, distinguished by the origin and location of fluid, and is classified as either cytotoxic or vasogenic [38] . The former is a neuronal form of swelling; fl uid accumulates in the cytosol. Vasogenic edema is caused by breakdown of the blood-brain barrier, resulting in fluid accumulation in the extracellular space. Reductions in the levels of either type of edema may improve neurobehavioral morbidity [39] and recirculation in the cerebral microvasculature [40, 41] . As we have shown in the present study, ECP treatment can effectively reduce the extent of edema; this limits the extent of ischemia-induced secondary damage and may have a role to play in neuroprotection against ischemic injury [42] .
In summary, we suggest that ECP plays a beneficial role in the treatment of cerebral ischemia and neurological deficits caused by this condition, at least partly by reducing the extent of brain edema, inhibiting neuronal apoptosis, and blocking the rise in cytotoxic [Ca 2+ ] i . It remains to be established whether ECP is also helpful in the treatment of other neurodegenerative conditions including parkinsonism and Alzheimer's disease. 
